Literature DB >> 33577560

TranSynergy: Mechanism-driven interpretable deep neural network for the synergistic prediction and pathway deconvolution of drug combinations.

Qiao Liu1, Lei Xie1,2,3,4.   

Abstract

Drug combinations have demonstrated great potential in cancer treatments. They alleviate drug resistance and improve therapeutic efficacy. The fast-growing number of anti-cancer drugs has caused the experimental investigation of all drug combinations to become costly and time-consuming. Computational techniques can improve the efficiency of drug combination screening. Despite recent advances in applying machine learning to synergistic drug combination prediction, several challenges remain. First, the performance of existing methods is suboptimal. There is still much space for improvement. Second, biological knowledge has not been fully incorporated into the model. Finally, many models are lack interpretability, limiting their clinical applications. To address these challenges, we have developed a knowledge-enabled and self-attention transformer boosted deep learning model, TranSynergy, which improves the performance and interpretability of synergistic drug combination prediction. TranSynergy is designed so that the cellular effect of drug actions can be explicitly modeled through cell-line gene dependency, gene-gene interaction, and genome-wide drug-target interaction. A novel Shapley Additive Gene Set Enrichment Analysis (SA-GSEA) method has been developed to deconvolute genes that contribute to the synergistic drug combination and improve model interpretability. Extensive benchmark studies demonstrate that TranSynergy outperforms the state-of-the-art method, suggesting the potential of mechanism-driven machine learning. Novel pathways that are associated with the synergistic combinations are revealed and supported by experimental evidences. They may provide new insights into identifying biomarkers for precision medicine and discovering new anti-cancer therapies. Several new synergistic drug combinations have been predicted with high confidence for ovarian cancer which has few treatment options. The code is available at https://github.com/qiaoliuhub/drug_combination.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33577560      PMCID: PMC7906476          DOI: 10.1371/journal.pcbi.1008653

Source DB:  PubMed          Journal:  PLoS Comput Biol        ISSN: 1553-734X            Impact factor:   4.475


  63 in total

Review 1.  Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives.

Authors:  Krishna C Bulusu; Rajarshi Guha; Daniel J Mason; Richard P I Lewis; Eugene Muratov; Yasaman Kalantar Motamedi; Murat Cokol; Andreas Bender
Journal:  Drug Discov Today       Date:  2015-09-07       Impact factor: 7.851

2.  Can we open the black box of AI?

Authors:  Davide Castelvecchi
Journal:  Nature       Date:  2016-10-06       Impact factor: 49.962

Review 3.  The challenge of drug resistance in cancer treatment: a current overview.

Authors:  Michail Nikolaou; Athanasia Pavlopoulou; Alexandros G Georgakilas; Efthymios Kyrodimos
Journal:  Clin Exp Metastasis       Date:  2018-05-24       Impact factor: 5.150

Review 4.  The search for synergy: a critical review from a response surface perspective.

Authors:  W R Greco; G Bravo; J C Parsons
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

5.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 7.  New anticancer agents: recent developments in tumor therapy.

Authors:  Riyasat Ali; Zeenat Mirza; Ghulam M D Ashraf; Mohammad Amjad Kamal; Shakeel Ahmed Ansari; Ghazi Abdullah Damanhouri; Adel Mohammad Abuzenadah; Adeel Ga Chaudhary; Ishfaq Ahmed Sheikh
Journal:  Anticancer Res       Date:  2012-07       Impact factor: 2.480

8.  Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.

Authors:  Robin M Meyers; Jordan G Bryan; James M McFarland; Barbara A Weir; Ann E Sizemore; Han Xu; Neekesh V Dharia; Phillip G Montgomery; Glenn S Cowley; Sasha Pantel; Amy Goodale; Yenarae Lee; Levi D Ali; Guozhi Jiang; Rakela Lubonja; William F Harrington; Matthew Strickland; Ting Wu; Derek C Hawes; Victor A Zhivich; Meghan R Wyatt; Zohra Kalani; Jaime J Chang; Michael Okamoto; Kimberly Stegmaier; Todd R Golub; Jesse S Boehm; Francisca Vazquez; David E Root; William C Hahn; Aviad Tsherniak
Journal:  Nat Genet       Date:  2017-10-30       Impact factor: 38.330

Review 9.  Drug resistance in cancer: an overview.

Authors:  Genevieve Housman; Shannon Byler; Sarah Heerboth; Karolina Lapinska; Mckenna Longacre; Nicole Snyder; Sibaji Sarkar
Journal:  Cancers (Basel)       Date:  2014-09-05       Impact factor: 6.639

10.  Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration.

Authors:  James M McFarland; Zandra V Ho; Guillaume Kugener; Joshua M Dempster; Phillip G Montgomery; Jordan G Bryan; John M Krill-Burger; Thomas M Green; Francisca Vazquez; Jesse S Boehm; Todd R Golub; William C Hahn; David E Root; Aviad Tsherniak
Journal:  Nat Commun       Date:  2018-11-02       Impact factor: 14.919

View more
  8 in total

1.  SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning.

Authors:  António J Preto; Pedro Matos-Filipe; Joana Mourão; Irina S Moreira
Journal:  Gigascience       Date:  2022-09-26       Impact factor: 7.658

2.  Prediction of Drug-Drug Interaction Using an Attention-Based Graph Neural Network on Drug Molecular Graphs.

Authors:  Yue-Hua Feng; Shao-Wu Zhang
Journal:  Molecules       Date:  2022-05-07       Impact factor: 4.927

3.  Rosmanol and Carnosol Synergistically Alleviate Rheumatoid Arthritis through Inhibiting TLR4/NF-κB/MAPK Pathway.

Authors:  Lianchun Li; Zhenghong Pan; Desheng Ning; Yuxia Fu
Journal:  Molecules       Date:  2021-12-23       Impact factor: 4.411

4.  A Cross-Level Information Transmission Network for Hierarchical Omics Data Integration and Phenotype Prediction from a New Genotype.

Authors:  Di He; Lei Xie
Journal:  Bioinformatics       Date:  2021-08-13       Impact factor: 6.937

Review 5.  The Road to Personalized Medicine in Alzheimer's Disease: The Use of Artificial Intelligence.

Authors:  Anuschka Silva-Spínola; Inês Baldeiras; Joel P Arrais; Isabel Santana
Journal:  Biomedicines       Date:  2022-01-29

6.  Deep learning prediction of chemical-induced dose-dependent and context-specific multiplex phenotype responses and its application to personalized alzheimer's disease drug repurposing.

Authors:  You Wu; Qiao Liu; Yue Qiu; Lei Xie
Journal:  PLoS Comput Biol       Date:  2022-08-11       Impact factor: 4.779

7.  NEXGB: A Network Embedding Framework for Anticancer Drug Combination Prediction.

Authors:  Fanjie Meng; Feng Li; Jin-Xing Liu; Junliang Shang; Xikui Liu; Yan Li
Journal:  Int J Mol Sci       Date:  2022-08-30       Impact factor: 6.208

8.  DCE-DForest: A Deep Forest Model for the Prediction of Anticancer Drug Combination Effects.

Authors:  Wei Zhang; Ziyun Xue; Zhong Li; Huichao Yin
Journal:  Comput Math Methods Med       Date:  2022-06-09       Impact factor: 2.809

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.